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Abstract
Background: Familial dilated cardiomyopathy (DCM) is genetically heterogeneous. Mutations in more than 40 genes
have been identified in familial cases, mostly inherited in an autosomal dominant pattern. DCM due to recessive
mutations is rarely observed. In consanguineous families, homozygosity mapping and whole exome sequencing (WES)
can be utilized to identify the genetic defects in recessively inherited DCM.
Methods: In a consanguineous family with four affected siblings with severe DCM, we combined homozygosity
mapping, linkage analysis and WES, to uncover the genetic defect.
Results: A region of homozygosity (ROH) on chromosome 8q24.13–24.23 was found to be shared by all of the four
affected siblings. WES detected ~47,000 variants that were filtered to a homozygous mutation (p.Gly243Arg) in the
FBXO32 gene, located within the identified ROH. The mutation segregated with the phenotype, replaced a highly-
conserved amino acid, and was not detected in 1986 ethnically-matched chromosomes. FBXO32, which encodes a
muscle-specific ubiquitin ligase, has been implicated in the pathogenesis of cardiomyopathy through the ubiquitin
proteasome system (UPS). In addition, FBXO32-knockout mice manifest with cardiomyopathy. Screening the
index patient for all of the WES variants in 48 genes known to be implicated in hypertrophic and dilated
cardiomyopathy was negative.
Conclusions: Our data suggest that FBXO32 is a candidate gene for recessive DCM. Acting as a cardiac
ubiquitin ligase, mutated FBXO32 could perturb the degradation of target proteins in the UPS, the impairment
of which has been observed in cardiomyopathy. Our work proposes that genes encoding other ubiquitin
ligases could also be implicated in familial cardiomyopathy.
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Background
Dilated cardiomyopathy (DCM; OMIM 115200), charac-
terized by impaired systolic function and left ventricular
enlargement, is considered to be the most common indi-
cation for cardiac transplantation [1, 2]. A familial pattern,
mostly inherited as autosomal dominant, has been
observed in about 20–35 % of DCM cases with remark-
able genetic heterogeneity; disease-associated mutations
have been identified in more than 40 genes [3, 4]. A reces-
sively inherited form of familial DCM is rarely observed
and is often associated with extra-cardiac manifestations
such as skeletal myopathy, hypotonia, hepatic encephalop-
athy, and impaired fatty acid oxidation defects.
The ubiquitin proteasome system (UPS) is crucial for
the regulation of cellular protein degradation. The target
proteins for degradation undergo an initial step of
polyubiquitination before their destruction by the 26S
proteasome [5]. The UPS cascade consists of three com-
ponents: a ubiquitin-activating enzyme (E1), a ubiquitin-
conjugating enzyme (E2), and a ubiquitin-ligase enzyme
(E3), which is the substrate-specific component of the
UPS. Impaired UPS has recently been implicated in the
pathogenesis of heart failure, cardiac ischemia, and car-
diomyopathy (CMP) [6, 7]. The protein encoded by
FBXO32, also known as atrogin-1 and MAFbx, is an E3
ligase that is expressed selectively in skeletal muscles
and cardiomyocytes and plays a critical role in muscle
atrophy [8, 9], as well as in the development of cardiac
hypertrophy and atrophy [10, 11]. In support of an asso-
ciation between deficient FBXO32 protein and CMP, a
recent study has shown that atrogin-1 knockout mice
develop CMP with intracellular protein accumulation
and cardiomyocyte apoptosis [12].
Methods
Subjects with cardiomyopathy
The index patient was a 26-year-old female who pre-
sented with a history of progressive shortness of breath
and easy fatigability for 2 months. On examination, her
vital signs revealed a blood pressure of 95/60 and a pulse
rate of 95 beats per minute. The jugular venous pressure
was 4 cm above the sternal angle. A heart examination
revealed normal first and second heart sounds with
blowing systolic murmur at the apex. The liver was palp-
able. There were no ascites or lower limb edema. A chest
X-ray revealed cardiomegaly and pulmonary edema, and a
12-lead electrocardiogram showed sinus tachycardia with
bifascicular block. An echocardiogram revealed a dilated
left ventricle with severe global hypokinesia and poor left
ventricular systolic function (Fig. 1). Despite maximal med-
ical therapy, she developed decompensated heart failure, for
which she underwent successful orthotropic heart trans-
plantation. Family screening with transthoracic echocardio-
grams revealed three affected siblings: two asymptomatic
sisters and one 14-year-old brother who had a history of
dyspnea and orthopnea but had never been evaluated
(Fig. 2, Table 1). Their parents and the other five siblings
had normal echocardiograms. None of the affected patients
had skeletal muscle weakness or abnormal creatine kinase
levels. The subjects were enrolled in the study after obtain-
ing written informed consent. This project was approved
by the Research Advisory Council at KFSH&RC.
Homozygosity mapping and linkage analysis
A recessive pattern of inheritance was assumed, because
the family was consanguineous, the parents had unre-
markable cardiac evaluations, and the disease affected
both sexes. Genomic DNA was extracted from whole-
blood samples obtained from all affected patients, their
parents, and unaffected siblings. SNP-based genotyping
was performed using AxiomTM CEU Human Array
from AffymetrixR (Santa Clara, CA, USA). To detect re-
gions of homozygosity (ROHs), SNPs were analyzed
using AutoSNPa software [13]. Conventionally, ROH are
defined as fragments where SNPs are homozygous for a
stretch of consecutive alleles in affected individuals, and
heterozygous, or homozygous for the other alleles, in
unaffected members of the same family. Multipoint
parametric linkage analysis was performed using Gene
Hunter Easy Linkage Analysis Software module 4.0. A
fully penetrant recessive model of inheritance was used,
with a population disease allele frequency of 0.0001 and
using Asian SNP allele frequencies.
Whole exome sequencing
Whole exome sequencing (WES) was performed on the
Illumina HiSeq 2000 platform. Samples were prepared
and enrichment was carried out according to Agilent's
SureSelect Protocols. Reads were mapped to the most
Fig. 1 M-mode echocardiographic recordings from the index patient
showing severe dilatation of the left ventricle (LVIDs: Left ventricle
internal diameter during systole; LVIDd: Left ventricle internal diameter
in diastole; both are markedly increased) and poor contractility with an
ejection fraction (EF) of 12.5 %
Al-Hassnan et al. BMC Medical Genetics  (2016) 17:3 Page 2 of 9
recent build of the human genome (hg19/b37) using the
Burrows-Wheeler Aligner package, version 0.6.2. Single
nucleotide polymorphisms (SNPs) and insertion/deletion
variants were called using the GATK Unified Genotyper
for each sample. Variants detected by WES were filtered
by restricting the analysis to homozygous changes within
the ROH, followed by excluding previously reported
polymorphisms (Fig. 3).
Candidate gene search and mutation screening
Using the UCSC and Ensembl genome browsers [14, 15],
the OMIM database [4], and the GeneDistiller2 software
[16], candidate genes were analyzed based on their func-
tion, expression, biological pathways, or animal models.
Genomic DNA of the affected patients, their parents,
and siblings was amplified by PCR using intronic
primers that were designed to flank (50–100 bp) the
coding exons of the identified gene, as defined by the
Ensembl Genome Browser [15]. PCR was performed
in a final volume of 20 μl containing approximately
10 ng of genomic DNA, using standard conditions
(primer sequences and conditions are available on re-
quest). Purified PCR amplicons covering the entire
coding region of the selected genes were directly se-
quenced with the dideoxy chain-termination method
using an ABI Prism Big Dye Terminator v3.1 Cycle
Sequencing Kit, following the manufacturer’s instruc-
tions, and processed on an ABI 3730XL capillary
Fig. 2 Family pedigree showing the four affected siblings (filled symbols). Haplotypes spanning 8q24.12–q24.21 are shown under each symbol
with two black arrows indicating the shared homozygous region between the affected individuals. The presence of the mutant allele (c.727G > C)
is indicated by (+). The index case is indicated by the red arrow. The number below the symbol represents the age (in years). Echocardiogram
was performed on the parents of the index case and all of their offspring
Table 1 Echocardiographic findings of the four affected individuals. EF: ejection fraction; FS: fractional shortening; LV: left ventricle;
LVDd: left ventricular diastolic diameter; MR: mitral regurgitation; RV: right ventricle; TR: tricuspid regurgitation; yrs: years
Individual Age (yrs) Echocardiogram EF LVDd FS
IV:2 26 severely dilated LV. severely reduced LV systolic function. moderate MR. 12.5 % 63 7.8 %
IV:3 22 moderately dilated LV. severely reduced LV systolic function. trace MR. 25 % 57 15.8 %
IV:5 20 moderately dilated LV. severely reduced LV systolic function. moderate MR. 25 % 59 16.9 %
IV:6 14 severely dilated LV and RV. severely reduced LV and RV systolic function. severe MR and TR 15 % 71 5.6 %
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sequencer (Applied Biosystems, CA, USA). Sequence
analysis was performed using the SeqMan 6.1 module
of the Lasergene (DNA Star Inc. WI, USA) software
package, then compared with the reference GenBank
sequence. Numbering commenced with the A of the
ATG initiation codon as +1.
Histopathology and immunohistochemistry
Histopathological and immunohistochemical studies were
performed on ventricular myocardial tissue from the
explanted heart of the proband, and on a control myocar-
dial specimen from a non-cardiomyopathy case. To assess
FBXO32 expression, a mouse monoclonal anti-human
FBXO32 antibody raised against amino acids 1–300 (Santa
Cruz Biotechnology, Dallas, Texas) was used for immuno-
histochemical staining. Antibody dilution was performed
according to the manufacturer’s protocol.
Results
Homozygosity mapping and linkage analysis
Homozygosity analysis identified a ROH (~17 Mb) on
chromosome 8q24.13–q24.23 (8:122,185,539-139,111,674)
that was shared by all of the four affected siblings (Fig. 4a).
This single ROH, which has 111 genes, was not shared by
their parents and the unaffected five siblings, and was the
only ROH across the genome that was found to be shared
by all of the affected siblings. Further analysis of the SNPs
within the detected ROH narrowed the critical region
to rs17288269 at 8:123,924,246 and rs13261097 at
8:125,185,945, which has 29 genes. All the SNPs
within this narrowed region were homozygous in all
the four affected siblings, except for one SNP
(rs17256536 at 8:124,768,356) in individual IV-3 and
another SNP (rs1080109 at 8:124,780,391) in individ-
ual IV-5. Linkage analysis verified this region with a
maximum LOD score of 3.37 for the two markers
rs16898165 and rs28522984, which are located at
8:124,232,985 and 8:124,351,429 (Fig. 4b).
Whole exome sequencing
WES of the index case identified 46,574 variants over-
lapping genes. Several steps to filter the variants were
implemented (Fig. 3). The results of linkage analysis
and homozygosity mapping were useful in restricting
the analysis to the single ROH that had been identi-
fied to be shared by all the affected individuals. The
extended ROH on chromosome 8q24 was found to
have 437 homozygous variants across the 17 Mb re-
gion. These variants were further filtered by excluding
reported polymorphisms in the dbSNP and 1000 Ge-
nomes databases, resulting in only two homozygous
variants; p.His356Tyr in OC90 and p.Gly243Arg in
FBXO32. The OC90 variant was excluded, as it is un-
likely to be implicated in CMP. The mouse ortholog
of OC90 has been shown to be specifically expressed
in the developing otocyst and to be involved in sens-
ing orientation relative to gravity [17]. In addition,
mice homozygous for a null Oc90 allele exhibit al-
tered otoliths and thin cupula, saccule, utricle and
tectorial membranes, and have no cardiac phenotype
[18]. The other variant identified, in FBXO32
(8:124,510,127-124,553,493), is more likely to be asso-
ciated with the cardiac phenotype in the family. In all
of the four affected siblings, a homozygous c.727G >
C mutation in the F-box domain was detected, result-
ing in the substitution of glycine with arginine at
amino acid position 243 (p.Gly243Arg, Fig. 5a). This
missense mutation segregated with the disease pheno-
type; the parents and four of the unaffected siblings
were heterozygous carriers while one unaffected sib-
ling was homozygous for the normal allele (Fig. 2).
The mutation was not found in 1986 chromosomes
from ethnically-matched normal controls.
We have also screened all the WES variants that
overlap 48 OMIM genes implicated in dilated and
hypertrophic familial CMP (Additional file 1: Table
S1). All of the identified 62 variants have been previ-
ously reported in the dbSNP and/or 1000 Genomes
databases as polymorphisms, except for two intronic
variants in the TTN and SGCD genes.
Fig. 3 Flowchart showing the several steps of filtering the variants
identified by whole exome sequencing. ROH: region of homozygosity
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Bioinformatics-based prediction analysis for functional
consequences of p.Gly243Arg
Several bioinformatics tools (Polyphen2 [19], PANTHER
[20], SNPs&GO [21], and I-Mutant [22]) were utilized to
predict the functional consequences of p.Gly243Arg
(c.727G > C). The Polyphen2 program predicted the vari-
ant to be probably damaging. According to the PANTHER
cSNP estimation, the change has a deleterious effect on
protein function with a score of −3.624. SNPs&GO ana-
lysis predicted the p.Gly243Arg change as “disease” with a
reliability score of 1, while I-Mutant predicted that the
change will reduce the stability of the protein with a score
of −0.67 (the “minus” score indicates reduced stability).
Protein sequence alignment of FBXO32 orthologs
demonstrated that the glycine residue is a conserved
amino acid down to zebrafish [14], suggesting that
this amino acid has an essential function (Fig. 5b).
We also modeled p.Gly243Arg of FBXO32 on a tem-
plate structure adapted from 2ovq (Fig. 5c). The ana-
lysis suggested that the replacement of the small and
more hydrophobic glycine with the large, polar and
less hydrophobic arginine may not only hinder nor-
mal protein folding, but also destabilize the protein,
as was also predicted by the I-Mutant algorithm.
Histopathology and immunohistochemistry
Histopathological analysis of the left ventricular myocar-
dial biopsy from the explanted heart of the proband
showed hypertrophied myocytes, often with bizarrely
shaped hyperchromatic nuclei and waving of the myo-
cytes (Fig. 6a and b). The immunohistochemical analysis
of the FBXO32 protein showed cytoplasmic staining
with reduced expression in the left ventricle of the index
case in comparison to a control myocardial specimen
from a non-cardiomyopathy case (Fig. 6e and f).
Discussion
In this work, we combined homozygosity mapping, link-
age analysis, and WES, to identify the genetic alteration
in a consanguineous family with a recessive form of
DCM. The identified homozygous mutation in the
FBXO32 gene was uncovered after homozygosity map-
ping, an approach that we adopted in this case in view
of the high probability of identifying a homozygous
mutation in a consanguineous family. The parents were
asymptomatic with normal echocardiograms, and the
disease affected both sexes.
The phenotype in the proband was remarkable, with
severe CMP progressing to heart failure that necessitated
heart transplantation. Screening family members by
echocardiogram revealed variable presentation: two sib-
lings were asymptomatic while the youngest affected
child had suggestive cardiac symptoms. This observation
underscores the importance of screening first-degree rel-
atives in cases of DCM.
The FXO32 gene is one of more than 38 members of
the FBXO (F-Box Only) family of proteins that have an
F-box domain characterized by approximately 50 amino
acids, which functions as a site for protein-protein inter-
action [23]. FBXO32 is one of the components of the E3
ubiquitin ligase SCF (Skp1, Cullin-1, F-box), which binds
target proteins for degradation by the UPS. The F-box
domain links the F-box protein to the other SCF compo-
nents by binding Skp1, leading to the destruction of the
target proteins. In animals, through enhancing protein
Fig. 4 a Analysis of the SNP data using AutoSNPa software identified a block of homozygosity (arrow) of about 17 Mb on chromosome
8q24.13–q24.23 (8:122,185,539-139,111,674) that was shared by all of the four affected siblings (left) and not found in their parents and
unaffected siblings (right). The horizontal axis indicates the chromosome numbers. The vertical axis indicates the LOD score. b GeneHunter Easy
Linkage analysis showing the identified locus on 8q24 with a maximum LOD score of 3.37. Homozygous variants are displayed in black. Heterozygous
variants are displayed in yellow
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Fig. 5 a The homozygous mutation (c.727G > C, p.G243R) is indicated by the arrow in the upper panel. The normal allele is shown in the lower
panel. b Protein sequence alignment of FBXO32 orthologs demonstrating that the glycine residue is a conserved amino acid down to zebrafish
(D. rerio). c In Silico Protein model generated using Expasy-based modeling tools. On the left, the color of the model is based on the size
properties of the amino acids. The color-coded polarity and hydrophobicity for the variant is given below the figure. The variant is predicted to
destabilize the structure
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degradation, Fbxo32 was initially discovered to play a
critical role in inducing muscle atrophy [8, 9].
Serving as a cardiac ubiquitin ligase, FBXO32 has
been implicated in the pathogenesis of CMP.6,7 FBXO32
has been shown to repress calcineurin through assembling
with the UPS complex, which promotes cardiac hyper-
trophy in response to pathologic stimuli [10]. Li et al. have
also found that over-expressed Fbxo32 in neonatal rat
cardiomyocytes disrupts the Akt-dependent pathway
responsible for physiological cardiac hypertrophy.11
Interestingly, down-regulation of Fbxo32 in knockout
mice produces the opposite effect, with the inhibition
of cardiac hypertrophy in response to pressure overload
[24], suggesting that there are different mechanisms by
which FBXO32 induces atrophy and hypertrophy in
cardiomyocytes [25]. In a recent study on atrogin-1
knockout mice, charged multivesicular body protein
2B (CHMP2B), which is part of an endosomal sorting
complex required for autophagy, has been identified
as a target of atrogin-1-mediated degradation.12 Mice
lacking atrogin-1 fail to degrade CHMP2B, resulting
in autophagy impairment, intracellular protein aggre-
gate accumulation, unfolded protein response activa-
tion and subsequent cardiomyocyte apoptosis, leading,
ultimately, to CMP and premature death.
Furthermore, in support of a potential link between
FBXO32 and DCM in this family, other cardiac ubiquitin li-
gases (MuRF1, MuRF2, MuRF3, CHIP, MDM2) have also
been implicated in the pathogenesis of cardiac hypertrophy,
atrophy, and ischemia reperfusion injury.5 Recently, muta-
tions in the cardiac ubiquitin ligase TRIM63, which encodes
MuRF1, have been identified in patients with familial hyper-
trophic CMP [26]. The expression of mutant TRIM63 was
associated with impaired UPS-mediated protein degrad-
ation in cardiomyocytes. This finding, together with our
work, suggests that the dysfunction of other proteins in the
UPS complexes may also be implicated in the pathogenesis
of Mendelian forms of CMP.
Fig. 6 a Hematoxylin and eosin (H&E) and (b) trichrome staining of a left ventricular myocardial biopsy from the explanted heart of the proband
showing hypertrophied myocytes, often with bizarrely shaped hyperchromatic nuclei and waving of the myocytes. c H&E and (d) trichrome
staining from the control myocardium showing no cardiomyopathic changes, disarray, or fibrosis. e and (f) Immunohistochemical analysis of
FBXO32 showing cytoplasmic staining with reduced protein expression in a section from the left ventricle of the proband (e) in comparison to a
control myocardial specimen (f)
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Although causality is yet to be established, several fac-
tors pertinent to the identified mutation (p.Gly243Arg)
support the suggestion that FBXO32 is a likely candi-
date gene for DCM. There was a clear co-segregation
of the mutation with the clinical phenotype. All of
the affected patients, but none of their parents and
unaffected siblings, were homozygous for the mutant
allele. In addition, the mutation, which replaces a
highly-conserved aliphatic non-polar amino acid with
a polar positively charged one, was not present in
1986 chromosomes, and was predicted to destabilize
the protein.
The identified homoallelic variant in the F-box
domain is likely to be a loss-of-function mutation.
Being within the F-box domain, this mutation may
cause loss of substrate specificity, leading to the pre-
mature degradation of functional proteins. It may also
cause loss of efficient recruitment of the components
of the UPS. However, a gain-of-function mechanism
is still a possibility, where the mutant allele could
lead to the accumulation of proteins that are dam-
aging. Both mechanisms would theoretically perturb
the well-controlled system of protein homeostasis
within cardiomyocytes, and lead to CMP.
It is noteworthy that none of the affected patients had
skeletal muscle weakness. The mutation identified in this
family may have damaged a cardiac-specific protein, and
hence the skeletal muscles are spared. However, further
studies in cell or animal models harboring this particular
mutation may provide a plausible explanation of the
mechanism of cardiac disease and of the apparent lack
of skeletal involvement.
The methodology that we have adopted in this study
has recognizable limitations. The family pedigree was
highly suggestive of a recessive pattern of inheritance,
and therefore we implemented the approach of homozy-
gosity mapping and WES, followed by excluding non-
homozygous variants. Although the recessive inheritance
conforms to the segregation of the disease in this family,
a dominant pattern with reduced penetrance remains a
possibility. In addition, the unaffected individuals may
still be in a presymptomatic phase of a late-onset CMP.
A long-term follow-up with periodic evaluation may
clarify if the identified variant is not fully penetrant. Last,
as our study was conducted in a single family, screening
FBXO32 in other families with CMP of unknown
etiology may provide more insight and establish the
causal relationship between FBXO32 and CMP.
Conclusions
Our work suggests that FBXO32 is a candidate gene for
recessive DCM. Further studies are still needed to estab-
lish the causal relationship. Genetic analysis for FBXO32
may be considered in families with recessively inherited
DCM of unknown genetic cause.
Additional file
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